Advanced search×

Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine

Biomed Pharmacother 63(9):6 (2009) PMID 19819100

Nifedipine (NFP) is an anti-hypersensitive drug and a well-known substrate of cytochrome P450 3A4 (CYP3A4), while cyclosporine (CSP) is a potent p-glycoprotein (P-gp) inhibitor. P-gp is a drug transporter, which determines the absorption and bioavailability of many drugs that are substrates for P-gp. Drugs that induce or inhibit P-gp may have a profound effect on the absorption and pharmacokinetics (PK) of drugs transported by P-gp within the body, possibly compromising their bioavailability. But the role of P-gp in the NFP efflux and its impact on PK profile is not known. Hence in our present study we attempted to investigate the effect of CSP on oral absorption and PK of NFP. Rhodamine 123 (Rho 123), a known P-gp substrate was used as a positive control. Male Wistar rats (350-400g) were used for the study. Rats were divided into 4 groups (n=6 each); one group was treated with vehicle (cremophor) followed by NFP (0.2mg/kg; i.v. bolus) and the other group with CSP (10mg/kg; i.v.) followed by NFP. Group 3 and 4 were treated with vehicle (cremophor) followed by Rho 123 (0.2mg/kg, i.v.) and CSP (10mg/kg; i.v.) followed by Rho 123 (0.2mg/kg, i.v.) respectively. The blood samples were collected at 0, 5, 10, 15, 30, 60, 90, 120, 180 and 240min after NFP administration. NFP concentrations in plasma were analyzed by LC-MS-MS and Rho 123 was analyzed by fluorimetric detector. NFP efflux was significantly decreased in CSP treated rats (49.1% decrease, Ps; 3.999 vs. 4.641l in NFP alone vs. CSP+NFP groups respectively). Thus the results indicate that NFP would belong to a group of P-gp substrate. The decrease in efflux of NFP by CSP, through inhibition of P-gp, into the intestinal lumen did not show any impact on PK. This could be due to the activity of other transporters and/or CYP3A4 may have more limiting role than P-gp on NFP metabolism and disposition that is why inhibiting P-gp did not lead to increase the bioavailability and PK alterations.

DOI: 10.1016/j.biopha.2009.04.031
Version: za2963e q8za8 q8zbc q8zcc q8zd0 q8zee q8zf5 q8zgb

Similar articles you may find interesting…

  1. Intrapulmonary pharmacokinetics of GSK2251052 in Healthy Volunteers.

    Antimicrob Agents Chemother (2013) PMID 23650164

    The plasma and intrapulmonary pharmacokinetics (PK) of intravenous (IV) GSK2251052, a novel, boron-containing antimicrobial, were evaluated in healthy adult subjects. Thirty subjects underwent bronchoscopy and timed bronchoalveolar lavage (BAL) following either a single dose (Cohort...
  2. Phase I pharmacokinetic and biodistribution study with escalating doses of (223)Ra-dichloride in men with castration-resistant metastatic pr...

    Eur J Nucl Med Mol Imaging (2013) PMID 23653243

    Pharmacokinetic studies showed rapid clearance of (223)Ra from the vasculature, with a median of 14 % (range 9-34 %), 2 % (range 1.6-3.9 %), and 0.5 % (range 0.4-1.0 %) remaining in plasma at the end of infusion, after 4 h, and after 24 h, respectively. Biodistribution studies showed early p...
  3. Mutation of the Mg2+ Transporter SLC41A1 Results in a Nephronophthisis-Like Phenotype.

    J Am Soc Nephrol (2013) PMID 23661805

    We overcome this limitation by combining homozygosity mapping with whole-exome resequencing in a sibling pair with an NPHP-related ciliopathy. Whole-exome capture revealed a homozygous splice acceptor site mutation (c.698G>T) in the renal Mg(2+) transporter SLC41A1. This mutation resulted in skippin...